Key Operational and Financial Highlights

Q1 FY27 Financial Performance

  • Total Revenue: Stood at ₹155.1 crores, representing a 6.5% decrease Year-on-Year (YoY).
  • Revenue Breakdown by End-User Segment:
  • Polymers: 48.7%
  • Specialty Chemicals: 22.5%
  • Pharma: 10.11%
  • Others: 18.7%
  • International Business Contribution: Accounted for 84.4% of total revenue.
  • Regional Mix: North America was the leading region, contributing more than 52% of revenue.
  • EBITDA: Stood at ₹24.1 crores, lower by 32.4% YoY.
  • EBITDA Margin: For the quarter was 15.6%.
  • Profit After Tax (PAT): Came in at ₹8.9 crores for the quarter.
  • Balance Sheet: As of June 2026, the company remains net debt-free with a strong balance sheet and healthy cash balance.

Business Environment and Strategy

Management described the global chemical industry as facing subdued demand, particularly in Europe and China, alongside volatility in energy and raw material prices. Geopolitical tensions in West Asia were noted as adding uncertainty. Despite this, the Indian chemical industry demonstrated resilience. The company's strategy is centered on product diversification and value addition beyond its core acid and alkyl chlorides.

Product Development and R&D Initiatives

  • New Product Focus: The company is actively developing products in new chemistries, including polymers, polymer modifiers/additives, multi-step sulfonation products, and chloro-fluoro compounds.
  • Polymer Development: Two high-end polymers are in development for mission-critical applications in medical implants, automotive, aerospace, electronics, semiconductors, and oil & gas. Another polymer is targeted for 3D printing filaments, hemodialysis membranes, water RO filtration, electronics insulation, and food processing.
  • Polymer Additives: Three products are under development. One is at the pilot stage, with customer production trials pending. Another is a coating/adhesive modifier based on biological raw materials (e.g., coconut oil, palm oil).
  • R&D Expansion: The company plans to double its Research and Development team and infrastructure in FY27. A multi-purpose pilot plant with four streams for complex chemistry scale-up is under design and expected to be operational in approximately 6-7 months (around February 2027).

Manufacturing and Operational Update

  • The company renewed its Responsible Care certification from the Indian Chemical Council for 3 years (July 2026 to July 2029).
  • The current manufacturing site at Ekalbara faces expansion limitations due to permitting challenges with the local government. Alternative locations like Dahej were considered but deemed crowded and challenging.

Growth Initiatives and Capex

  • New Manufacturing Site: The company is considering a greenfield expansion and has expressed interest in acquiring land in a notified zone in Odisha. A detailed feasibility report is being prepared for submission to the Odisha government. Board approval is pending.
  • Capex Plan: A planned investment of approximately ₹250 crores over 5-6 years for the Odisha facility, with an expected payback period of 4-5 years. The project timeline, pending approvals, anticipates construction could start by November 2026, with commercial production likely in 1.5 to 2 years.
  • Historical Capex: Over the past 5-6 years, approximately ₹200 crores was spent largely on maintenance (replacing old, corroded plants) and debottlenecking (e.g., expanding captive thionyl chloride capacity), not on revenue-generating growth projects.

Contract Update with Arclin (ex-DuPont)

  • The long-term supply contract previously with DuPont has been fully assigned to Arclin. Supplies are continuing unchanged.
  • Discussions for the contract renewal are scheduled to begin between the last quarter of calendar year 2026 and the first quarter of calendar year 2027.
  • Management expressed confidence in renewal based on a 9-year history of flawless quality and delivery but acknowledged preparing for a worst-case scenario of non-renewal, which would be a significant blow requiring time to recover volumes.
  • The contract operates on a cost-plus, formula-based pricing model. Raw material cost fluctuations (and forex changes) are passed through. Recent volumes from Arclin have been higher this quarter.

Guidance and Outlook

  • FY27 Revenue Growth: Management expects revenue to be 15% to 20% higher than FY26. This growth is anticipated from new acid chloride products (e.g., one product contributed ₹4 crores in FY26 and is expected to contribute ₹15 crores in FY27).
  • Medium-Term Goal: The company has a strategy to double its business size over the next 5 years.
  • Margin Target: The company aims to maintain EBITDA margins between 15% and 20%, acknowledging inherent volatility in the chemical industry.
  • Q2 FY27 Update: The company is currently operating at full permission utilization across all sites (Transpek and 3 job work sites) in the ongoing quarter.

Investment in Silox

  • The company holds an investment in Silox valued at approximately ₹300 crores, which is illiquid due to a shareholders' agreement.
  • Attempts to monetize this investment have been challenging. Silox is reportedly planning its own significant investments (in Dahej and Odisha), making a cash buyback unlikely in the near future.
  • The investment yields a dividend of between ₹5-7 crores annually.

Other Key Points from Q&A

  • Capacity Utilization: Explained that despite plants running at 100% of permitted levels, overall capacity utilization often appears as 70-82% in reports due to the product-specific nature of capacities and sales mix.
  • Competitive Landscape: Addressed pricing pressures in the acid chloride market but emphasized the company's ability to sustain relationships and margins despite new entrants in India over the past 6-7 years.
  • AI in R&D: The company is exploring building AI models to simulate trials and expedite the product development process.